http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-0800058-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116e27c1f9b7a18ed4b98f820c0b14f1 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4453 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 |
| filingDate | 2008-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11e43b39003207a7f8fe40bffd1dae66 |
| publicationDate | 2009-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-0800058-A2 |
| titleOfInvention | Pharmaceutical combination for reducing obesity |
| abstract | The present invention relates to a combination of drugs that inhibit central cannabinoid receptors with a reduced side effect. The drug combination is a drug that inhibits central cannabinoid receptors, in particular an appetite suppressant, or a desired and possibly pharmaceutically acceptable acid addition salt and / or solvate thereof, and a compound of formula (I) wherein Arii is phenyl, naphthyl, or pyridyl, X is halogen, and then Y is a hydroxyl group or X is a nitrogen atom, and then Y is a bond between this nitrogen atom and the carbon atom adjacent to Y, thereby forming a six-membered oxadiazing ring, R and R1 together with the adjacent nitrogen atom form a 5-7 membered saturated heterocyclic group, or the compound Contains N-oxide or a pharmaceutically acceptable acid addition salt thereof in addition to the carrier (s) commonly used in the preparation of the medicament. X Y R I I / ΑγιΊ-0 = Ν-Ο-0Η2-0Η-0Η2-Ν (I) L. |
| priorityDate | 2008-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.